Inhibitors of heat shock protein 70 (Hsp70) with enhanced metabolic stability reduce tau levels.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 22 11 2020
revised: 30 03 2021
accepted: 04 04 2021
pubmed: 12 4 2021
medline: 18 9 2021
entrez: 11 4 2021
Statut: ppublish

Résumé

The molecular chaperone, Heat Shock Protein 70 (Hsp70), is an emerging drug target for neurodegenerative diseases, because of its ability to promote degradation of microtubule-associated protein tau (MAPT/tau). Recently, we reported YM-08 as a brain penetrant, allosteric Hsp70 inhibitor, which reduces tau levels. However, the benzothiazole moiety of YM-08 is vulnerable to metabolism by CYP3A4, limiting its further application as a chemical probe. In this manuscript, we designed and synthesized seventeen YM-08 derivatives by systematically introducing halogen atoms to the benzothiazole ring and shifting the position of the heteroatom in a distal pyridine. In microsome assays, we found that compound JG-23 has 12-fold better metabolic stability and it retained the ability to reduce tau levels in two cell-based models. These chemical probes of Hsp70 are expected to be useful tools for studying tau homeostasis.

Identifiants

pubmed: 33839251
pii: S0960-894X(21)00251-1
doi: 10.1016/j.bmcl.2021.128025
pmc: PMC8805511
mid: NIHMS1774016
pii:
doi:

Substances chimiques

Benzothiazoles 0
HSP70 Heat-Shock Proteins 0
Thiazolidines 0
YM-08 compound 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

128025

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS059690
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Nat Neurosci. 2015 Aug;18(8):1183-9
pubmed: 26192747
Nat Rev Drug Discov. 2009 Oct;8(10):783-93
pubmed: 19794442
J Am Chem Soc. 2010 Sep 1;132(34):11906-7
pubmed: 20687558
Cell Chem Biol. 2016 Aug 18;23(8):992-1001
pubmed: 27499529
J Biol Chem. 2004 Feb 6;279(6):4869-76
pubmed: 14612456
Hum Mol Genet. 2015 Jul 15;24(14):3971-81
pubmed: 25882706
Biol Psychiatry. 2013 Sep 1;74(5):367-74
pubmed: 23607970
Future Med Chem. 2011 Sep;3(12):1523-37
pubmed: 21882945
Biochim Biophys Acta. 2005 Jan 3;1739(2-3):268-79
pubmed: 15615645
J Biol Chem. 2010 May 28;285(22):16798-805
pubmed: 20308058
Nat Med. 2015 Oct;21(10):1154-62
pubmed: 26390242
Adv Pharmacol. 2012;64:1-25
pubmed: 22840743
Bioorg Med Chem. 2009 Feb 15;17(4):1709-15
pubmed: 19138859
ACS Chem Neurosci. 2013 Jun 19;4(6):930-9
pubmed: 23472668
Chem Commun (Camb). 2011 Jan 7;47(1):529-31
pubmed: 21082080
Trends Mol Med. 2009 Mar;15(3):112-9
pubmed: 19246243
Cold Spring Harb Perspect Med. 2018 Jan 2;8(1):
pubmed: 28159830
J Neurosci. 2009 Sep 30;29(39):12079-88
pubmed: 19793966
Acta Neuropathol Commun. 2016 Sep 29;4(1):106
pubmed: 27687527
J Med Chem. 2018 Jul 26;61(14):6163-6177
pubmed: 29953808
Bioorg Med Chem Lett. 2020 Mar 1;30(5):126954
pubmed: 31952963
Aging Cell. 2019 Oct;18(5):e13000
pubmed: 31267651
J Mol Biol. 2011 Aug 19;411(3):614-32
pubmed: 21708173
Hum Mol Genet. 2012 Aug 1;21(15):3500-12
pubmed: 22556362
Hum Mol Genet. 2014 Jan 1;23(1):104-16
pubmed: 23962722
Autophagy. 2012 Apr;8(4):609-22
pubmed: 22361619
Science. 1998 Dec 4;282(5395):1914-7
pubmed: 9836646

Auteurs

Hao Shao (H)

Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Electronic address: haoshaodream@hotmail.com.

Xiaokai Li (X)

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, United States; Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States.

Shigenari Hayashi (S)

Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States.

Jeanette L Bertron (JL)

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, United States; Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States.

Daniel M C Schwarz (DMC)

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, United States; Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States.

Benjamin C Tang (BC)

Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States.

Jason E Gestwicki (JE)

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158, United States; Institute for Neurodegenerative Disease, University of California San Francisco, San Francisco, CA 94158, United States. Electronic address: Jason.gestwicki@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH